Plasma thiols and taurine levels in central retinal vein occlusion

Current Eye Research

Volumn 35, Issue 7, 2010, Pages 644-650

  Pinna, Antonio ^a   Zinellu, Angelo ^a,b   Franconi, Flavia ^a   Carru, Ciriaco ^a  

^a UNIVERSITY OF SASSARI   (Italy)

^b Porto Conte Ricerche Srl   (Italy)

Author keywords

Central retinal vein occlusion; Cysteine; Cysteinylglycine; Glutamylcysteine; Glutathione; Homocysteine; Laser induced fluorescence capillary electrophoresis; Taurine

Indexed keywords

CHOLESTEROL; CREATININE; CYANOCOBALAMIN; CYSTEINE; CYSTEINYLGLYCINE; FOLIC ACID; GAMMA GLUTAMYLCYSTEINE; GLUTATHIONE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HOMOCYSTEINE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TAURINE; TRIACYLGLYCEROL; DIPEPTIDE; GAMMA-GLUTAMYLCYSTEINE; LIPID; THIOL DERIVATIVE;

ADULT; ARTICLE; CAPILLARY ELECTROCHROMATOGRAPHY; CENTRAL RETINA VEIN OCCLUSION; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; FEMALE; FLUORESCENCE; FOLIC ACID BLOOD LEVEL; HUMAN; LASER; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PRIORITY JOURNAL; RISK ASSESSMENT; STUDENT T TEST; VITAMIN BLOOD LEVEL; WILCOXON SIGNED RANKS TEST; AGED; BLOOD; CAPILLARY ELECTROPHORESIS; CASE CONTROL STUDY; CLASSIFICATION; MIDDLE AGED; RETINA VEIN OCCLUSION;

AGED; CASE-CONTROL STUDIES; CREATININE; CYSTEINE; DIPEPTIDES; ELECTROPHORESIS, CAPILLARY; FEMALE; GLUTATHIONE; HUMANS; LIPIDS; MALE; MIDDLE AGED; RETINAL VEIN OCCLUSION; SULFHYDRYL COMPOUNDS; TAURINE;

EID: 77954416539     PISSN: 02713683     EISSN: 14602202     Source Type: Journal    
DOI: 10.3109/02713681003698863     Document Type: Article

References (38)

1. Clarkson JG. Central retinal vein occlusion. In: Ryan SJ (ed.), Medical Retina. 3rd edn, Vol.2. St. Louis: Mosby Inc., 2001, pp. 1368-1375.
2. Klein R, Moss SE, Meuer SM, Klein BE. The 15-year cumulative incidence of retinal vein occlusion: the Beaver Dam Eye Study. Arch Ophthalmol 2008;126:513-518. (Pubitemid 351549845)
3. The Eye Disease Case-Control Study Group. Risk factors for central retinal vein occlusion. Arch Ophthalmol 1996;114:545-554. (Pubitemid 26136347)
4. Cahill MT, Stinnett SS, Fekrat S. Meta-analysis of plasma homocysteine, serum folate, serum vitamin B(12), and thermolabile MTHFR genotype as risk factors for retinal vascular occlusive disease. Am J Ophthalmol 2003;136:1136-1150. (Pubitemid 37485782)
5. McGimpsey SJ, Woodside JV, Cardwell C, Cahill M, Chakravar-thy U. Homocysteine, methylenetetrahydrofolate reductase C677T polymorphism, and risk of retinal vein occlusion: a meta-analysis. Ophthalmology 2009;116:1778-1787.e1.
6. McGimpsey SJ, Woodside JV, Bamford L et al. Retinal vein occlusion, homocysteine, and methylene tetrahydrofo-late reductase genotype. Invest Ophthalmol Vis Sci 2005;46: 4712-4716. (Pubitemid 44264574)
7. Pinna A, Carru C, Zinellu A et al. Plasma homocysteine and cysteine levels in retinal vein occlusion. Invest Ophthalmol Vis Sci 2006;47:4067-4071. (Pubitemid 46044326)
8. Pinna A, Zinellu A, Franconi F, Solinas G, Carru C. Decreased plasma cysteinylglycine and taurine levels in branch retinal vein occlusion. Ophthalmic Res 2010;43:26-32.
9. Mayer EL, Jacobsen DW, Robinson K. Homocysteine and coronary atherosclerosis. J Am Coll Cardiol 1996;27:517-527. (Pubitemid 26081913)
10. Zinellu A, Pinna A, Zinellu E et al. High-throughput capillary electrophoresis method for plasma cysteinylglycine measurement: evidences for a clinical application. Amino Acids 2008;34:69-74.
11. Zinellu A, Sotgia S, Scanu B et al. Taurine determination by capillary electrophoresis with laser-induced fuorescence detection: from clinical feld to quality food applications. Amino Acids 2009;36:35-41.
12. Dickinson DA, Forman HJ. Cellular glutathione and thiols metabolism. Biochem Pharmacol 2002;64:1019-1026.
13. Worden JA, Stipanuk MH. A comparison by species, age and sex of cysteinesulfnate decarboxylase activity and taurine concentration in liver and brain of animals. Comp Biochem Physiol, B 1985;82:233-239.
14. Vine AK. Hyperhomocysteinemia: a new risk factor for central retinal vein occlusion. Trans Am Ophthalmol Soc 2000;98:493-503. (Pubitemid 32059520)
15. Marcucci R, Bertini L, Giusti B et al. Thrombophilic risk factors in patients with central retinal vein occlusion. Thromb Haemost 2001;86:772-776. (Pubitemid 32834184)
16. Weger M, Stanger O, Deutschmann H et al. Hyperhomocyst(e) inemia and MTHFR C677T genotypes in patients with central retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol 2002;240:286-290. (Pubitemid 36075597)
17. Lattanzio R, Sampietro F, Ramoni A et al. Moderate hyper-homocysteinemia and early-onset central retinal vein occlusion. Retina (Philadelphia, Pa) 2006;26:65-70. (Pubitemid 44391754)
18. Gao W, Wang YS, Zhang P, Wang HY. Hyperhomocysteine-mia and low plasma folate as risk factors for central retinal vein occlusion: a case-control study in a Chinese population. Graefes Arch Clin Exp Ophthalmol 2006;244:1246-1249. (Pubitemid 44463461)
19. Narayanasamy A, Subramaniam B, Karunakaran C et al. Hyperhomocysteinemia and low methionine stress are risk factors for central retinal venous occlusion in an Indian population. Invest Ophthalmol Vis Sci 2007;48:1441-1446. (Pubitemid 351261323)
20. Di Crecchio L, Parodi MB, Sanguinetti G, Iacono P, Ravalico G. Hyperhomocysteinemia and the methylenetet-rahydrofolate reductase 677C-T mutation in patients under 50 years of age affected by central retinal vein occlusion. Ophthalmology 2004;111:940-945. (Pubitemid 38586688)
21. Nygård O, Refsum H, Ueland PM, Vollset SE. Major lifestyle determinants of plasma total homocysteine distribution: the Hordaland Homocysteine Study. Am J Clin Nutr 1998;67:263-270. (Pubitemid 28076718)
22. Ueland PM. Homocysteine species as components of plasma redox thiol status. Clin Chem 1995;41:340-342.
23. Verhoef P, Stampfer MJ, Buring JE et al. Homocysteine metabolism and risk of myocardial infarction: relation with vitamins B6, B12, and folate. Am J Epidemiol 1996;143:845-859. (Pubitemid 26131092)
24. Araki A, Sako Y, Fukushima Y et al. Plasma sulfhydryl-con-taining amino acids in patients with cerebral infarction and in hypertensive subjects. Atherosclerosis 1989;79:139-146. (Pubitemid 19226322)
25. Mansoor MA, Bergmark C, Svardal AM, Lønning PE, Ueland PM. Redox status and protein binding of plasma homocysteine and other aminothiols in patients with early-onset peripheral vascular disease. Homocysteine and peripheral vascular disease. Arterioscler Thromb Vasc Biol 1995;15:232-240.
26. Kugiyama K, Ohgushi M, Motoyama T et al. Intracoronary infusion of reduced glutathione improves endothelial vaso-motor response to acetylcholine in human coronary circulation. Circulation 1998;97:2299-2301. (Pubitemid 28280382)
27. Lapenna D, de Gioia S, Ciofani G et al. Glutathione-related antioxidant defenses in human atherosclerotic plaques. Circulation 1998;97:1930-1934. (Pubitemid 28222187)
28. Morrison JA, Jacobsen DW, Sprecher DL et al. Serum gluta-thione in adolescent males predicts parental coronary heart disease. Circulation 1999;100:2244-2247.
29. Zinellu A, Zinellu E, Sotgia S et al. Factors affecting S-homo-cysteinylation of LDL apoprotein B. Clin Chem 2006;52:2054-2059. (Pubitemid 44658207)
30. McCully KS, Wilson RB. Homocysteine theory of arteriosclerosis. Atherosclerosis 1975;22:215-227.
31. Ferretti G, Bacchetti T, Moroni C et al. Effect of homocystei-nylation of low density lipoproteins on lipid peroxidation of human endothelial cells. J Cell Biochem 2004;92:351-360. (Pubitemid 38058601)
32. Tan B, Jiang DJ, Huang H et al. Taurine protects against low-density lipoprotein-induced endothelial dysfunction by the DDAH/ADMA pathway. Vascul Pharmacol 2007;46: 338-345. (Pubitemid 46386501)
33. Murakami S, Yamagishi I, Asami Y et al. Hypolipidemic effect of taurine in stroke-prone spontaneously hypertensive rats. Pharmacology 1996;52:303-313. (Pubitemid 26162790)
34. Murakami S, Kondo-Ohta Y, Tomisawa K. Improvement in cholesterol metabolism in mice given chronic treatment of taurine and fed a high-fat diet. Life Sci 1999;64:83-91. (Pubitemid 29012752)
35. Murakami S, Kondo Y, Sakurai T, Kitajima H, Nagate T. Tau-rine suppresses development of atherosclerosis in Watanabe heritable hyperlipidemic (WHHL) rabbits. Atherosclerosis 2002;163:79-87. (Pubitemid 34615728)
36. Zulli A, Lau E, Wijaya BP et al. High dietary taurine reduces apoptosis and atherosclerosis in the left main coronary artery: association with reduced CCAAT/enhancer binding protein homologous protein and total plasma homocysteine but not lipidemia. Hypertension 2009;53:1017-1022.
37. Soukoulis V, Dihu JB, Sole M et al. Micronutrient def-ciencies an unmet need in heart failure. J Am Coll Cardiol 2009;54:1660-1673.
38. El-Khairy L, Ueland PM, Refsum H, Graham IM, Vollset SE; European Concerted Action Project. Plasma total cysteine as a risk factor for vascular disease: The European Concerted Action Project. Circulation 2001;103: 2544-2549. (Pubitemid 32521962)